Compare HLMN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLMN | IVA |
|---|---|---|
| Founded | 1964 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.1B |
| IPO Year | 2020 | N/A |
| Metric | HLMN | IVA |
|---|---|---|
| Price | $8.45 | $5.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $11.60 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.1M | 425.8K |
| Earning Date | 04-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.22 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,552,224,000.00 | N/A |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $4.67 | $1,062.21 |
| P/E Ratio | $43.28 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $6.63 | $2.94 |
| 52 Week High | $10.85 | $7.98 |
| Indicator | HLMN | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 49.99 |
| Support Level | $8.48 | $3.86 |
| Resistance Level | $10.31 | $5.78 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 61.66 | 59.32 |
Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the company are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the U.S, Canada and Mexico.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.